{"brief_title": "Safety and Antiviral Study of ACH126, 433 (b-L-Fd4C) in Adults With Lamivudine-resistant Chronic Hepatitis B", "brief_summary": "The purpose of this study is to determine the safety and antiviral HBV activity of ACH126, 433 (b-L-Fd4C) in the treatment of adults with lamivudine-resistant chronic Hepatitis B.", "detailed_description": "Evaluation of safety and antiviral activity of 3 dose levels of ACH126, 443 over a twelve week treatment in the population described.", "condition": "Chronic Hepatitis B", "intervention_type": "Drug", "intervention_name": "ACH126, 433 (b-L-Fd4C)", "criteria": "Inclusion Criteria - Adults \u2265 18 years of age - Chronic HBV infection, known to be HbsAg positive \u2265 6 months - On lamivudine, either 100 or 150 mg daily for the treatment of chronic hepatitis B infection and - Exhibit a 2-3 log decrease in HBV DNA levels followed by a rebound of at least 1.5 log HBV DNA or - Achieved an HBV DNA level of <10,000 copies/mL HBV DNA on at least 2 occasions and have rebounded to > 100,000 copies/mL HBV DNA, or - Have a demonstrable 3TC resistant genotype regardless of treatment history. - HBeAG positive - HIV negative - Serum ALT \u22651.5 and \u226410x times upper limit of normal - HGB \u226510g/dl or HCT \u226530% (in the absence of blood transfusions or erythropoietin treatment in the preceding two weeks) - Platelet count >75,000/mm(^3), (in the absence of ongoing G-CSF therapy) - Serum creatinine <1.1 times upper limit of normal (ULN) - Negative radiologic screening test (ultrasound, CT scan or MRI) for hepatocellular carcinoma (HCC) within 6 months prior to entry - PT/INR<2 - Subjects of reproductive capability must utilize an approved forms of birth control - All women of child-bearing capability must have a negative serum or urine pregnancy test (minimum sensitivity of 24 IU/L of b-HCG) within 72 hours prior to the start of study medication - Subjects must be able to provide written informed consent - Subject must be available for follow-up for a period of 20 weeks Exclusion Criteria - HIV infection - Hepatitis C co-infection - Alcohol abuse - Pregnancy or breast-feeding - Inability to tolerate oral medication - Any clinical condition or prior therapy that, in the Investigator's opinion, would make the subject unsuitable for the study or unable to comply with the dosing requirements - Use of any investigational drug - Patients with decompensated liver disease - Use of any concomitant herbal treatments", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00040144.xml"}